| KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, ... Annals of Oncology 31 (12), 1746-1754, 2020 | 179 | 2020 |
| Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives E Krasniqi, G Barchiesi, L Pizzuti, M Mazzotta, A Venuti, M Maugeri-Saccà, ... Journal of hematology & oncology 12, 1-26, 2019 | 122 | 2019 |
| Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma F Goeman, F De Nicola, S Scalera, F Sperati, E Gallo, L Ciuffreda, ... Journal of Thoracic Oncology 14 (11), 1924-1934, 2019 | 74 | 2019 |
| Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives G Barchiesi, M Mazzotta, E Krasniqi, L Pizzuti, D Marinelli, E Capomolla, ... International journal of molecular sciences 21 (10), 3528, 2020 | 67 | 2020 |
| A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab A Botticelli, M Salati, FR Di Pietro, L Strigari, B Cerbelli, IG Zizzari, R Giusti, ... Journal of Translational Medicine 17, 1-8, 2019 | 57 | 2019 |
| Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study G Bon, L Pizzuti, V Laquintana, R Loria, M Porru, C Marchiò, E Krasniqi, ... Journal of Experimental & Clinical Cancer Research 39, 1-14, 2020 | 49 | 2020 |
| A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study T Gamucci, L Pizzuti, C Natoli, L Mentuccia, I Sperduti, M Barba, D Sergi, ... Cancer Biology & Therapy 20 (2), 192-200, 2019 | 44 | 2019 |
| KEAP1 and TP53 frame genomic, evolutionary, and immunologic subtypes of lung adenocarcinoma with different sensitivity to immunotherapy S Scalera, M Mazzotta, G Corleone, F Sperati, I Terrenato, E Krasniqi, ... Journal of Thoracic Oncology 16 (12), 2065-2077, 2021 | 39 | 2021 |
| KEAP1-Mutant NSCLC: the catastrophic failure of a cell-protecting hub S Scalera, M Mazzotta, C Cortile, E Krasniqi, R De Maria, F Cappuzzo, ... Journal of Thoracic Oncology 17 (6), 751-757, 2022 | 36 | 2022 |
| Long-term safety and real-world effectiveness of trastuzumab in breast cancer M Mazzotta, E Krasniqi, G Barchiesi, L Pizzuti, F Tomao, M Barba, P Vici Journal of clinical medicine 8 (2), 254, 2019 | 36 | 2019 |
| Prognostic relevance of neutrophil to lymphocyte ratio (NLR) in luminal breast cancer: a retrospective analysis in the neoadjuvant setting A Grassadonia, V Graziano, L Iezzi, P Vici, M Barba, L Pizzuti, G Cicero, ... Cells 10 (7), 1685, 2021 | 29 | 2021 |
| Circulating HPV DNA in the management of oropharyngeal and cervical cancers: current knowledge and future perspectives E Krasniqi, M Barba, A Venuti, L Pizzuti, F Cappuzzo, L Landi, S Carpano, ... Journal of Clinical Medicine 10 (7), 1525, 2021 | 28 | 2021 |
| Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence E Krasniqi, L Pizzuti, G Barchiesi, D Sergi, S Carpano, C Botti, R Kayal, ... Journal of Cellular Physiology 235 (11), 7900-7910, 2020 | 27 | 2020 |
| Exploring the role of respiratory microbiome in lung cancer: A systematic review F Perrone, L Belluomini, M Mazzotta, M Bianconi, V Di Noia, F Meacci, ... Critical Reviews in Oncology/Hematology 164, 103404, 2021 | 25 | 2021 |
| Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: a real‐world experience L Pizzuti, A Giordano, A Michelotti, M Mazzotta, C Natoli, T Gamucci, ... Journal of Cellular Physiology 234 (6), 7708-7717, 2019 | 24 | 2019 |
| Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting C Mandoj, L Pizzuti, D Sergi, I Sperduti, M Mazzotta, L Di Lauro, A Amodio, ... Journal of translational medicine 16, 1-9, 2018 | 24 | 2018 |
| The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression S Buglioni, E Melucci, F Sperati, M Pallocca, I Terrenato, F De Nicola, ... Oncoimmunology 7 (8), e1457602, 2018 | 21 | 2018 |
| Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study F Nelli, A Fabbri, A Onorato, D Giannarelli, MA Silvestri, JRG Berrios, ... Annals of Oncology 33 (1), 107-108, 2022 | 20 | 2022 |
| Eribulin in triple negative metastatic breast cancer: critic interpretation of current evidence and projection for future scenarios L Pizzuti, E Krasniqi, G Barchiesi, M Mazzotta, M Barba, A Amodio, ... Journal of Cancer 10 (24), 5903, 2019 | 20 | 2019 |
| Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: Current evidence and literature-based meta-analysis of randomized trials D Marinelli, M Mazzotta, L Pizzuti, E Krasniqi, T Gamucci, C Natoli, ... Cancers 12 (9), 2497, 2020 | 16 | 2020 |
